Form 4: Vor Biopharma CFO Nathan Jorgensen Reports Stock Disposal for Tax Obligations
SEC Form 4 Filing
Vor Biopharma's CFO, Nathan D. Jorgensen, disposed of 6,310 shares of common stock to cover tax withholding obligations related to the settlement of restricted stock units.
Summary
- On March 1, 2024, Nathan D. Jorgensen, the Chief Financial Officer of Vor Biopharma Inc., disposed of 6,310 shares of common stock.
- The disposal was executed to satisfy tax withholding obligations related to the settlement of restricted stock units.
- The price per share was $2.27.
- Following the transaction, Jorgensen directly owns 191,154 shares of Vor Biopharma Inc.
Sentiment
Score: 5
Explanation: This is a routine transaction related to tax obligations, so it's neutral in sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. This provides transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of the transaction (stock disposal) |
| 03/05/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.